Literature DB >> 2416676

The effect of interferon treatment of targets on susceptibility to cytotoxic T-lymphocyte killing: augmentation of allogeneic killing and virus-specific killing relative to viral antigen expression.

M J Blackman, A G Morris.   

Abstract

The effect on CTL lysis of treatment of CTL targets with IFNs has been investigated. Treatment of targets for alloreactive CTL with either IFN-alpha beta or IFN-gamma markedly augmented cytotoxicity. Cold competition experiments implied that CTL recognized the same target structure on both untreated and IFN-treated cells. This augmented lysis is presumably caused by IFN increasing expression of target MHC antigens. In the case of SFV-specific lysis of SFV-infected fibroblasts, IFN-alpha beta or IFN-gamma treatment somewhat reduced CTL lysis, but less so than Ab + C lysis which was abolished at moderate IFN concentrations; in the case of SFV-infected lymphoblastoid cells, CTL lysis remained the same or was slightly increased, whilst Ab + C lysis was reduced at moderate IFN concentrations and abolished at high IFN concentration; in the case of MSV/MLV-infected fibroblasts, CTL lysis was moderately increased whilst Ab + C lysis was decreased. IFN therefore increases virus-specific CTL cytotoxicity relative to viral antigen expression.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2416676      PMCID: PMC1453759     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  20 in total

Review 1.  Antiviral activity of interferons.

Authors:  R M Friedman
Journal:  Bacteriol Rev       Date:  1977-09

2.  Interferon enhances T cell mediated cytotoxicity of H-2 compatible target cells infected with UV-inactivated herpes simplex virus.

Authors:  K K Sethi; H Brandis
Journal:  Arch Virol       Date:  1978       Impact factor: 2.574

3.  Establishment and characterization of a cloned line of C3H mouse embryo cells sensitive to postconfluence inhibition of division.

Authors:  C A Reznikoff; D W Brankow; C Heidelberger
Journal:  Cancer Res       Date:  1973-12       Impact factor: 12.701

4.  Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system.

Authors:  R M Zinkernagel; P C Doherty
Journal:  Nature       Date:  1974-04-19       Impact factor: 49.962

5.  Department of Biological Sciences, University of Warwick, Coventry, CV47AL, England.

Authors:  G J Atkins; M D Johnston; L M Westmacott; D C Burke
Journal:  J Gen Virol       Date:  1974-12       Impact factor: 3.891

6.  The virulence of original and derived strains of Semliki forest virus for mice, guinea-pigs and rabbits.

Authors:  C J Bradish; K Allner; H B Maber
Journal:  J Gen Virol       Date:  1971-08       Impact factor: 3.891

7.  Electrophoretically pure mouse interferon exerts multiple biologic effects.

Authors:  I Gresser; J De Maeyer-Guignard; M G Tovey; E De Maeyer
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

8.  Interferon treatment of mice: enhanced expression of histocompatibility antigens on lymphoid cells.

Authors:  P Lindahl; I Gresser; P Leary; M Tovey
Journal:  Proc Natl Acad Sci U S A       Date:  1976-04       Impact factor: 11.205

9.  Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis.

Authors:  G Trinchieri; D Santoli
Journal:  J Exp Med       Date:  1978-05-01       Impact factor: 14.307

10.  Interferon enhances the susceptibility of virus-infected fibroblasts to cytotoxic T cells.

Authors:  J F Bukowski; R M Welsh
Journal:  J Exp Med       Date:  1985-01-01       Impact factor: 14.307

View more
  9 in total

Review 1.  Interferon-zeta/limitin: novel type I interferon that displays a narrow range of biological activity.

Authors:  Kenji Oritani; Yoshiaki Tomiyama
Journal:  Int J Hematol       Date:  2004-11       Impact factor: 2.490

Review 2.  Heart transplantation: cellular and humoral immunity.

Authors:  M L Rose; M H Yacoub
Journal:  Springer Semin Immunopathol       Date:  1989

3.  The effect of interferon-gamma treatment of rat tumour cells on their susceptibility to natural killer cell, macrophage and cytotoxic T-cell killing.

Authors:  H Yeoman; R A Robins
Journal:  Immunology       Date:  1988-02       Impact factor: 7.397

4.  MHC antigen expression in sequential biopsies from cardiac transplant patients--correlation with rejection.

Authors:  A Suitters; M Rose; A Higgins; M H Yacoub
Journal:  Clin Exp Immunol       Date:  1987-09       Impact factor: 4.330

5.  Mechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: cytotoxic T cells.

Authors:  S Martin; B Moss; P W Berman; L A Laskey; B T Rouse
Journal:  J Virol       Date:  1987-03       Impact factor: 5.103

6.  Human gamma interferon production by cytotoxic T lymphocytes sensitized during hepatitis A virus infection.

Authors:  K Maier; P Gabriel; E Koscielniak; Y D Stierhof; K H Wiedmann; B Flehmig; A Vallbracht
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

7.  Lytic susceptibility of target cells to cytotoxic T cells is determined by their constitutive major histocompatibility complex class I antigen expression and cytokine-induced activation status.

Authors:  M Ritter; C Huber; J Auböck; H Pohl-Markl; J Troppmair; M Herold; A Gächter; W Nussbaumer; G Böck; D Nachbaur
Journal:  Immunology       Date:  1994-04       Impact factor: 7.397

8.  Role of interferon-gamma in T-cell responses to Semliki Forest virus-infected murine brain cells.

Authors:  P T Tomkins; G A Ward; A G Morris
Journal:  Immunology       Date:  1988-03       Impact factor: 7.397

Review 9.  The Significance of Interferon-γ in HIV-1 Pathogenesis, Therapy, and Prophylaxis.

Authors:  Shannon R Roff; Ezra N Noon-Song; Janet K Yamamoto
Journal:  Front Immunol       Date:  2014-01-13       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.